ADAR1 Capital Management »

4d Molecular Therapeutics In shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of 4d Molecular Therapeutics In (FDMT) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in 4d Molecular Therapeutics In

Tip: Access up to 7 years of quarterly data

All positions including 4d Molecular Therapeutics In held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in 4d Molecular Therapeutics In by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-09-30 $65k 6.0k 10.81
2024-06-30 $42k 2.0k 20.99
2024-03-31 $64k 2.0k 31.86

More positions owned by ADAR1 Capital Management

Cytokinetics Com New (CYTK)
Protagonist Therapeutics (PTGX)
Bridgebio Pharma (BBIO)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Immunovant (IMVT)
Royalty Pharma Shs Class A (RPRX)
Keros Therapeutics (KROS)
Ascendis Pharma A/s Sponsored Adr (ASND)
Zura Bio Class A Ord Shs (ZURA)
Zai Lab Adr (ZLAB)
Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA)
Aa Mission Acquisition Corp Ord Shs Cl A (AAM)
Mineralys Therapeutics (MLYS)
Syndax Pharmaceuticals (SNDX)

View all positions for ADAR1 Capital Management

Top funds holding 4d Molecular Therapeutics In

BVF
RA Capital Management
BlackRock
VR Adviser
Deep Track Capital
Goldman Sachs Group
Henderson Group
Vanguard Group
State Street Corporation
Novo A/S
Redmile Group
Braidwell
Casdin Capital
Geode Capital Management
Polar Capital Holdings

View all funds holding 4d Molecular Therapeutics In